Sep. 20 at 9:59 PM
$FATE The leading role of
$FATE in the autoimmune CAR-T race became more prominent after
$NVS and
$BMY recently paused their autoimmune CAR-T programs, which caused patient deaths and severe toxicities. Fate Therapeutics (FT819 / FT839) has many unique advantages, including a quality-controlled iPSC master cell bank (millions of doses); CRISPR TRAC-targeted (non-viral); FDA CDRP & RMAT; full-speed enrollment for a pivotal phase 2 trial; mild or no conditioning chemotherapy; same-day outpatient discharge, which will dominate as the first mass-market, off-the-shelf, outpatient therapy for Lupus. Buy and hold strong! 🤑🤑🤑 Cheers! 🤞✌️
